On December 7, 2023 Sarah Cannon Research Institute (SCRI) reported that more than 80 abstracts and presentations have been selected for inclusion at the 65th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition. Hosted in San Diego and online from Dec. 9-12, the meeting is the year’s most comprehensive global hematology event (Press release, Sarah Cannon Research Institute, DEC 7, 2023, View Source [SID1234638277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At this year’s ASH (Free ASH Whitepaper) Annual Meeting & Exposition, SCRI investigators, including physicians from The US Oncology Network, will discuss groundbreaking research in malignant and non-malignant blood cancer, CAR T-Cell therapy, real-world outcomes, and targeted immunotherapies.

"We look forward to sharing our research insights, including the latest developments in the treatment of sickle cell disease, immune effector cell therapy, and other novel therapies that are advancing the way we treat blood cancers and blood disorders," said Howard A. "Skip" Burris, III, MD, President, SCRI. "We are proud to share these important updates through the work of more than 65 investigators from across our network, which can only be done through the power of collaboration."

In November 2022, McKesson and HCA Healthcare formed a joint venture combining SCRI with former US Oncology Research, the research arm of The US Oncology Network. The collaboration brings together physicians who are actively enrolling patients into clinical trials at more than 250 locations in 24 states across the U.S. More than 65 investigators from the joint venture will present insights at this year’s Annual Meeting. Separately, Ontada, McKesson’s oncology real-world data and evidence, clinical education, and provider technology business, is also presenting two posters at the conference.

Featured presentations include:

Haydar Frangoul, MD, MS, Sarah Cannon Pediatric Hematology/Oncology & Cellular Therapy Program at TriStar Centennial Medical Center, is first author on an oral presentation titled, "Exagamglogene Autotemcel for Severe Sickle Cell Disease" to be shared on Monday, December 11 at 4:30 p.m. (presentation time 4:45 p.m.) PST.

This presentation will include important updates from CLIMB SCD-121, an ongoing, 24-month, phase 3 trial of exa-cel in patients age 12-35 with sickle cell disease.

Dr. Frangoul is also co-author on an oral presentation titled, "Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia" to be shared on Monday, December 11 at 4:30 p.m. (presentation time 5:00 p.m.) PST.

____________________________________________________________________________

Chris Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Jason Melear, MD, Texas Oncology, John M. Burke, MD, Rocky Mountain Cancer Centers, Habte A. Yimer, MD, Texas Oncology, Mihir Raval, MD, New York Oncology Hematology, Miguel Islas-Ohlmayer, MD, St. Elizabeth Healthcare, Mitul Gandhi, MD, Virginia Cancer Specialists, and John Scott Renshaw, MD, Texas Oncology, are co-authors on the oral presentation, "Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study" presented on Sunday, December 10 at 4:30 p.m. (presentation time 4:45 p.m.) PST.

John M. Burke, MD, Rocky Mountain Cancer Centers, Mitul Gandhi, MD, Virginia Cancer Specialists, and Christopher A. Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, will highlight "Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)" through an oral presentation on Sunday, December 10 at 4:30 p.m. (presentation time 5:30 p.m.) PST.

These studies represent two arms of significant clinical trials exploring treatment advancements in classical Hodgkin Lymphoma (both advanced and early stage).

____________________________________________________________________________

Tonya Cox, BSN, Sarah Cannon Transplant & Cellular Therapy Network, is first author alongside seventeen SCRI/Sarah Cannon Transplant & Cellular Therapy Network co-authors on an oral presentation titled, "Standardization of Outpatient Care after CAR-T Therapy Across a Large Cell Therapy Network- Through Technology and Decentralized Virtual Nurses: Preliminary Results" which will be presented on Saturday, December 9 at 2:00 p.m. PST.

This study describes the innovative care model of using remote patient monitoring to provide chimeric antigen receptor T-cell therapies in the outpatient setting across a network of cell therapy centers.

____________________________________________________________________________

Jeffrey Matous, MD, Colorado Blood Cancer Institute, is first author on an oral presentation titled, "Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study" which will be shared on Monday, December 11 at 4:30 p.m. PST.

This presentation will offer an update out of a Phase I study for patients with relapsed/refractory multiple myeloma.

____________________________________________________________________________

Paul Shaughnessy, MD, Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital, is a co-author on a late-breaking oral presentation, titled, "Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507" which will be presented on Tuesday, December 12 at 9:00 a.m. PST.

This presentation presents the results of a Phase II multi-center single-arm prospective clinical trial of haploidentical transplantation in adults with severe sickle cell disease.

____________________________________________________________________________

A full list of presentations can be found here. Investigators highlighting research at this year’s ASH (Free ASH Whitepaper) Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, and partners from The US Oncology Network and Ontada.